Effect of vitamin E and selenium supplement on paraoxonase-1 activity, oxidized low density lipoprotein and antioxidant defense in diabetic rats

BioImpacts

Volumn 1, Issue 2, 2011, Pages 121-128

  Ghaffari, Tayibeh ^a   Nouri, Mohammad ^a   Irannejad, Ebrahim ^b   Rashidi, Mohammad Reza ^c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF TABRIZ   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Oxidative stress; Oxidized LDL; Paraoxonase 1; Selenium; Streptozotocin Induced diabetes; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ARYLDIALKYLPHOSPHATASE 1; CORN OIL; GLUCOSE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; SODIUM SELENITE; STREPTOZOCIN; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ERYTHROCYTE; FEMALE; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; LIPID PEROXIDATION; NONHUMAN; RAT; TREATMENT DURATION; VITAMIN SUPPLEMENTATION;

ANIMALIA; RATTUS; ZEA MAYS;

EID: 84862658386     PISSN: 22285652     EISSN: 22285660     Source Type: Journal    
DOI: 10.5681/bi.2011.016     Document Type: Article

References (44)

1. Al-Shamsi M, Amin A and Adeghate E. 2006. Vitamin E ameliorates some biochemical parameters in normal and diabetic rats. Ann N Y Acad Sci, 1084, 411-31.
2. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, et al. 1999. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved byantioxidants. Free Radic Biol Med, 26(7-8), 892-904.
3. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL and La Du BN. 1998. Paraoxonase inhibits highdensity lipoprotein oxidation and preserves its function: a possible peroxidative role for paraoxonase. J Clin Invest, 101(8), 1581-90.
4. Bergmeier C, Siekmeier R and Gross W. 2004. Distribution spectrum of paraoxonase activity in HDL fractions. Clin Chem, 50(12), 2309-15.
5. Blevs J, Navas-Acien A and Guallar E. 2007. Serum selenium and diabetes in U.S. adults. Diabetes Care, 30(4), 829-34.
6. Burstein M, Scholnick HR and Morfin R. 1970. Rapid method for isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res, 11(6), 583-95.
7. Chait A, Brazg RL, Tribble DL and Krauss RM. 1993.Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med, 94(4), 350-356.
8. Drabkin DL. 1965. The molecular weight of haemoglobin, its iron and nitrogen content and optical properties-their relevance in the problem of a reference standard for haemoglobin measurement. Bibl Haematol, 21, 33-42.
9. Durrington PN, Mackness B and Mackness MI. 2001. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol, 21(4), 473-80.
10. Fairbanks V and Klee GG. 1994.Biochemical aspects of haematology. In: Tietz Textbook of Clinical Chemistry (Burtis CA, AshwoodER, eds.) WB Saunders, Philadelphia; p. 2020-1.
11. Feldman EL. 2003. Oxidative stress and diabetic neuropathy: a new understanding of an old problem. J Clin Invest, 111(4), 431-3.
12. Folmer V, Soares JC and Rocha JB. 2002. Oxidative stress in mice is dependent on the free glucose content of the diet. Int J Biochem Cell Biol, 34(10), 1279-85.
13. Fridewald WJ, Levy RJ and Fredrikson DS. 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem, 18(6), 499-502
14. Girona J, Manzanares JM, Marimon F, Cabre A, Heras M, Guardiola M, et al. 2008. Oxidized to non-oxidized lipoprotein ratios are associated with arteriosclerosis and the metabolic syndrome in diabetic patients. Nutr Metab Cardiovasc Dis, 18(5), 380-7.
15. Haidara MA, Mikhailidis DP, Rateb MA, Ahmed ZA, Yassin HZ, Ibrahim IM, et al. 2009. Evaluation of the effect of oxidative stress and vitamin E supplementation on renal function in rats with streptozotocin-induced Type 1 diabetes. J Diabetes Complications, 23(2), 130-6.
16. Heijmans BT, Westendorp RGJ, Lagaay AM, Knook DL, Kluft C and Slagboom PE. 2000. Common paraoxonase gene variants, mortality risk and fatal cardiovascular events in elderly subjects. Atherosclerosis, 149(1), 91-7.
17. Heinecke JW. 2009. The HDL proteome: a marker and perhaps mediator of coronary artery disease. J Lipid Res, 50, 167-71.
18. Ikeda Y, Suehiro T, Inoue M, Nakauchi Y, Morita T, Arii K, et al. 1998. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism, 47(5), 598-602.
19. Inoue T, Uchida T, Kamishirado H, Takayanagi K, Hayashi T and Morooka S. 2001. Clinical significance of antibody against oxidizedlow density lipoprotein in patients with atheroscleroticcoronaryartery disease. J Am Coll Cardiol, 37(3), 775-9.
20. Jafarnejad A, Bathaie SZ, Nakhjavani M andHassan MZ. 2008. Effect of spermine on lipid profile and HDL functionality in the streptozotocin-induced diabetic rat model. Life Sciences, 82(5-6), 301-7.
21. Jakubowski H. 2000. Calcium-dependent human serum homocysteinethiolactonehydrolase: a protective mechanism against protein N-homocysteinylation. J BiolChem, 275(6), 3957-62.
22. King GL and Loeken MR. 2004. Hyperglycemia-induced oxidative stress in diabetic complications. Histochem Cell Biol, 122(4), 333-8.
23. Kondo A, Manabe M, Saito K, Maekawa M and Kanno T. 2002. Insulin treatment prevents LDL from accelerated oxidation in patients with diabetes. J Atheroscler Thromb, 9(6), 280-7.
24. Lukacinova A, Mojzis J, BenackaR, Keller J, Maguth T, Kurila P, et al. 2008. Preventive Effects of Flavonoids on Alloxan-Induced Diabetes Mellitus in Rats. Acta Vet Brno, 77, 175-82.
25. Mackness MI, Arrol S, Abbott C and Durrington PN. 1993. Protection of low-density lipoprotein againstoxidativemodification by high-density lipoprotein associated paraoxonase. Atherosclerosis, 104(1-2), 129-35.
26. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, et al. 1991. Serum paraoxonaseactivity in familial hypercholesterolemia and insulin-dependent diabetes mellitus.Atherosclerosis, 86(2-3), 193-9.
27. Mackness MI, Mackness B, Durrington PN, Connelly PW and Hegele RA. 1996. Paraoxonase:biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol, 7(2), 69-76.
28. Mahay S, Adeghate E, Lindley M, Rolph C and Singh J. 2004. Streptozotocin-induced type 1 diabetes mellitus alters the morphology, secretary function and acyl lipid contents in the isolated rat parotid salivary gland. Mol Cell Biochem, 261(1-2), 175-81.
29. Maritim AC, Sanders RA and Watkins JB. 2003. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol, 17(1), 24-38.
30. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V and Milner A. 1993. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci (Lond), 84(4), 407-12.
31. Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, et al. 2007. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation,115(11), 1481-501.
32. Nofer J. 2002. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis, 161(1), 1-16.
33. Ohkawa H, Ohishi N andYagi K. 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem, 95(2), 351-8.
34. Paglia DE and Valentine WN. 1967. Studies on the quantitative and qualitative charachtristication of erythrocyte GPX. J Lab Clin Med,70(1), 158-69.
35. Ramakrishna V and Jailkhani R. 2007. Evaluation of oxidative stress in Insulin Dependent Diabetes Mellitus (IDDM) patients. Diagn Pathol, 2, 22.
36. Ramesh B and Pugalendi KV. 2006. Antihyperglycemic Effect of Umbelliferone in Streptozotocin-Diabetic Rats. J Med Food, 9(4), 562-6.
37. Rozenberg O and Aviram M. 2006. S-Glutathionylation regulates HDL-associated paraoxonase 1 (PON1) activity. Biochem Biophys Res Commun, 351(2), 492-8.
38. Rozenberg O, Shiner M, Aviram M and Hayek T. 2008. Paraoxonase 1 (PON1) attenuates diabetes development in mice through its antioxidative properties. Free Radic Biol Med, 44(11), 1951-9.
39. Sargeant LA, Wareham NJ, Bingham S, Day NE, Luben RN, Oakes S, et al. 2000. Vitamin C and hyperglycemia in the European Prospective Investigation into Cancer-Norfolk (EPIC-Norfolk) study: a population-based study. Diabetes Care, 23(6), 726-32.
40. Selvakumar E, Prahalathan C, Mythili Y and Varalakshmi P. 2005. Beneficial effects of DL-alpha-lipoic acid on cyclophosphamide-induced oxidative stress in mitochondrial fractions of rat testis. Chem Biol Interact, 152(1), 59-66.
41. Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, Combs GF, et al. 2007. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: A randomized trial. Ann Intern Med, 147(4), 217-23.
42. Will JC, Ford ES and Bowman BA. 1999. Serum vitamin C concentrations and diabetes: findings from the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr, 70(1), 49-52.
43. Wu JH, Ward NC, Indrawan AP, Almeida CA, Hodgson JM, Proudfoot JM, et al. 2007. Effects of alpha-tocopherol and mixed tocopherol supplementation on markers of oxidative stress and inflammation in type 2 diabetes. Clin Chem, 53(3), 511-9.
44. Yanardag R, Ozsoy-Sacan O, Ozdil S and Bolkent S. 2007. Combined effects of vitamin C, vitamin E, and sodium selenate supplementation on absolute ethanol-induced injury in various organs of rats. Int J Toxicol, 26(6), 513-23.